AIXN
AiXin Life International, Inc.0.4840
+0.3200+195%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
12.10MP/E (TTM)
-Basic EPS (TTM)
-0.12Dividend Yield
0%Recent Filings
8-K
Director Wang resigns abruptly
10-Q
Q3 FY2025 results
AiXin Life's Q3 revenue plunged 68% y/y to $302K from $936K, with all segments—direct sales down 87%, pharmacy 94%, hotel 29%, manufacture 64%—hit by China's economic slowdown, yet operating loss narrowed 42% to $347K on 58% lower costs. YTD revenue fell 63% to $1.2M, operating loss widened to $1.8M, net loss $1.4M or $(0.057)/share versus $(0.053) last year; EPS reconciles to 25M shares. Cash dwindled to $19K after $1.8M operating burn, offset by $1.7M net related-party funding amid $5.5M due to insiders and $6.8M working capital gap. Hotel now holds 45% of sales. Customer concentration persists.
10-Q
Q2 FY2025 results
AiXin Life's Q2 revenue plunged 65% y/y to $460.9k, driven by 91% drops in direct sales and 90% in pharmacies amid economic headwinds, while manufacture held 63% share yet turned loss-making. Operating loss widened to $810.6k from $268.8k as fixed costs lingered; net loss hit $351.5k, narrowed by $463k gain on fixed asset disposals (per cash flow statement). Cash fell to $29.6k, offset by $2.3M related-party advances, leaving $4.5M due them (demand, non-interest bearing). Working capital deficit sits at $6.4M. Segments falter together. Cash burn stings.
10-Q
Q1 FY2025 results
AiXin Life's Q1 revenue plunged 53% y/y to $398.8K, led by 88% drops in direct sales and 85% in pharmacies amid China's economic slowdown, while manufacture held at $261.5K (66% of total). Operating loss widened 10% y/y to $682K on fixed costs outpacing sales cuts; net loss hit $722K versus $604K last year, driven by other expenses like $33K. Cash stayed flat at $63K, propped by $676K related-party financing against $676K operating burn. Stockholders' deficit deepened to $5.0M. One customer dominated 45% of sales. PRC policy shifts pose risks.
10-K
FY2024 results
AiXin Life posted FY2024 revenue of $3.8M, down 6% y/y, with Q4 manufacturing sales via Runcangsheng accelerating to drive 50% of total amid direct sales and pharmacy softening from economic headwinds. Pharmacy margins leaped to 32% cost of sales (derived), flipping to operating profit, while Runcangsheng's gross margins improved to 30%—yet hotel downtime from relocation deepened losses. Cash drained to $62K amid $1.6M operating outflow; related-party funding sustained ops. Runcangsheng lost $1.5M. No outlook disclosed. Intense competition threatens market share.
IPO
Website
Employees
Sector
Industry
AHG
Akso Health Group
1.23-0.05
CFOO
CHINA FOODS HOLDINGS LTD
0.66+0.00
COSM
Cosmos Health Inc.
0.50+0.09
DIT
AMCON Distributing Company
112.90+0.90
HIRU
Hiru Corp.
0.00+0.00
HLF
Herbalife Ltd.
14.45-0.45
IVFH
Innovative Food Holdings, Inc.
0.32-0.02
NAII
Natural Alternatives Internatio
3.19-0.01
NATR
Nature's Sunshine Products, Inc
22.38-0.85
UNFI
United Natural Foods, Inc.
32.86+0.40